Epigallocatechin-3-gallate Attenuates Renal Damage by Suppressing Oxidative Stress in Diabetic db/db Mice
Table 1
Changes in BW, KW/BW, glucose, and insulin levels in mice after different treatment.
Normal
Control
EGCG A
EGCG B
BW (g)
Baseline
25.2 ± 0.6
33.2 ± 0.8
33.4 ± 1.0
33.3 ± 1.1
Week 4
31.4 ± 1.3
39.8 ± 1.4
38.9 ± 1.9
39.5 ± 1.7
Week 8
35.3 ± 1.1
45.6 ± 1.2
44.2 ± 1.8
44.3 ± 3.1
KW/BW (mg/g)
Baseline
3.5 ± 0.4
6.5 ± 0.2
6.3 ± 0.5
6.4 ± 0.4
Week 4
3.6 ± 0.4
8.1 ± 0.3
7.1 ± 0.8
7.3 ± 0.1
Week 8
4.0 ± 0.6
8.4 ± 0.1
7.4 ± 0.2
7.5 ± 0.1
Glucose (mmol/L)
Baseline
4.9 ± 0.3
11.5 ± 0.9
11.3 ± 1.1
11.5 ± 1.1
Week 4
4.5 ± 0.9
15.1 ± 0.5
12.8 ± 1.0
12.1 ± 0.6
Week 8
4.7 ± 0.8
17.2 ± 0.8
14.4 ± 1.0
14.2 ± 0.7
Insulin (ng/mL)
Baseline
3.3 ± 1.3
5.6 ± 1.4
5.4 ± 1.1
5.7 ± 0.8
Week 4
3.2 ± 0.7
5.5 ± 1.1
7.8 ± 0.8
8.0 ± 0.9
Week 8
3.5 ± 1.1
5.2 ± 1.7
11.2 ± 2.2
12.4 ± 1.6
Note: normal, C57BLKS/J normal nontreated mice; control, C57BLKS/J db/db nontreated mice; EGCG A, db/db mice treated with EGCG of 50 mg/kg/d; EGCG B, db/db mice treated with EGCG of 100 mg/kg/d; BW, body weight; KW/BW, kidney weight/body weight; glucose, fasting plasma glucose; insulin, fasting plasma insulin; and versus normal; and versus control; values are means ± SEM. At baseline and at week 4, in each group; at week 8, in each group.
